Physician profile
Mark Hyde
NPI 1811960271
$702.23
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $36.02 · 2021: $390 · 2022: $53.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caldera Medical, INC | $317.05 | 2021 | |
| Therapeuticsmd, INC. | $69.52 | 2019-2022 | |
| Allergan, INC. | $61.71 | 2019-2021 | |
| Coopersurgical, INC. | $58.97 | 2019 | |
| Avion Pharmaceuticals | $48.29 | 2019 | |
| Coloplast Corp | $43.03 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.50 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $18.84 | 2021 | |
| Abbvie INC. | $18.75 | 2022 | |
| Myovant Sciences INC. | $18.66 | 2022 | |
| Astellas Pharma US INC | $15.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hyde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.